Publications

This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.

Data from RCTs and real-world data were compared to emphasise the safety and efficacy of baricitinib. Adverse event data is comparable between the two groups, with the exception of herpes zoster infections, which was lower in real-world populations.